Loading insider details...
Beta
Latest Form 4 (Aug 3, 2026): Exercise/Conversion of 27,948 ALKS shares, $1.31M.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 3, 2026 | Alkermes plc. (ALKS) | Exercise/Conversion | 27,948 | $1.31M |
| May 23, 2026 | Alkermes plc. (ALKS) | Exercise/Conversion | 6,142 | n/a |
| Jun 2, 2025 | Alkermes plc. (ALKS) | Exercise/Conversion | 8,013 | n/a |
| May 23, 2025 | Alkermes plc. (ALKS) | Grant/Award | 13,474 | n/a |
| May 16, 2025 | Lyra Therapeutics, Inc. (LYRA) | Grant/Award | 32,000 | n/a |
| Nov 15, 2024 | Axonics, Inc. (AXNX) | Disposition to Issuer | 14,944 | $1.06M |
| Nov 12, 2024 | Axonics, Inc. (AXNX) | Gift | 5,000 | n/a |
| Jul 1, 2024 | Alkermes plc. (ALKS) | Exercise/Conversion | 6,104 | n/a |
| Jun 14, 2024 | Lyra Therapeutics, Inc. (LYRA) | Grant/Award | 30,000 | n/a |
| Jun 4, 2024 | Alkermes plc. (ALKS) | Other (see footnotes) | 548 | $25.6K |